This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsVapotherm（VAPO）株式概要医療技術企業であるVapotherm, Inc.は、米国内外で呼吸困難に苦しむ様々な年齢の患者を治療するために使用される独自の高速療法製品の開発と商業化に注力している。 詳細VAPO ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 キャッシュランウェイが1年未満である 過去5年間で収益は年間10.3%減少しました。 意味のある時価総額がありません ( $14M )すべてのリスクチェックを見るVAPO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$2.1789.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-98m124m2016201920222025202620282031Revenue US$69.7mEarnings US$9.3mAdvancedSet Fair ValueView all narrativesVapotherm, Inc. 競合他社Trinity BiotechSymbol: NasdaqGS:TRIBMarket cap: US$13.1mNeuroMetrixSymbol: NasdaqCM:NUROMarket cap: US$9.0mScientific IndustriesSymbol: OTCPK:SCNDMarket cap: US$9.1mCue HealthSymbol: NasdaqCM:HLTHMarket cap: US$14.7m価格と性能株価の高値、安値、推移の概要Vapotherm過去の株価現在の株価US$2.1752週高値US$3.4452週安値US$0.70ベータ-1.11ヶ月の変化0.59%3ヶ月変化2.60%1年変化-22.22%3年間の変化-98.97%5年間の変化-97.04%IPOからの変化-98.30%最新ニュースお知らせ • Sep 20Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC executed the non binding term sheet to acquire Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on April 29, 2024. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. from a group of shareholders for $15.2 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Upon termination of the Merger Agreement under certain specified circumstances, Vapotherm will be required to pay Perceptive a termination fee of $1.0 million. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The board of directors of Perceptive also approved the agreement. The transaction is expected to close in the second half of 2024. Eric Blanchard and Amelia Runyan Davis of Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor and fairness opinion provider to the Special Committee and Paul Kinsella and Sarah Young of Ropes & Gray LLP is acting as legal counsel to the Vapotherm. Haim Zaltzman and Daniel Mun of Latham & Watkins LLP acted as legal counsel for SLR Investment Corp., public fund managed by SLR Capital Partners, LLC. Vapotherm has retained Morrow Sodali LLC, a proxy solicitor, to solicit proxies in connection with the Special Meeting at a cost of approximately $20,000 plus expenses. Scalar received a fee of $140,000 from Vapotherm for providing its services and rendering its opinion. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on September 20, 2024. Effective as of the closing of the merger, trading of Vapotherm’s common stock has been suspended on OTCQX, and Vapotherm has requested that its common stock be delisted from OTCQX. Vapotherm shareholders approved the transaction on September 19, 2024.お知らせ • Jun 18Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The transaction is expected to close in the second half of 2024. Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor to the Special Committee and Ropes & Gray LLP is acting as legal counsel to the Vapotherm.お知らせ • Mar 15Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADEVapotherm, Inc. announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference. The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th. The device is designed to reduce hospital readmissions, improve patient quality of life, and reduce HME costs for late-stage hypercapnic COPD patients. In addition to VAPS and volume control/assist ventilation modes and Vapotherm's proven high velocity therapy, the ventilator incorporates a built-in medical grade humidifier and integrated Bluetooth pulse oximetry and spirometry. The Access365 Home Ventilation Solution also includes cloud connectivity to enable remote data retrieval and system upgrades and a patient engagement platform which breaks the cycle of symptom exacerbation and readmission through early identification of worsening symptoms allowing more rapid clinical intervention. This proprietary algorithm resulted in up to a 41% reduction in late-stage COPD hospital readmissions. Vapotherm anticipates receiving FDA clearance for Access365 in early 2025.お知らせ • Dec 15The New York Stock Exchange to Commence Delisting Proceedings against VapothermThe New York Stock Exchange (‘NYSE’, the ‘Exchange’) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Vapotherm, Inc. (the ‘Company’) from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s common stock pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.お知らせ • Nov 11Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023Vapotherm, Inc. revised revenue guidance for the full Year 2023. The Company now expects full year revenue to be between $69 million and $71 million, a decrease from the Company’s previous fiscal outlook of $70 million to $73 million.お知らせ • Nov 02Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023Vapotherm, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023最新情報をもっと見るRecent updatesお知らせ • Sep 20Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC executed the non binding term sheet to acquire Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on April 29, 2024. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. from a group of shareholders for $15.2 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Upon termination of the Merger Agreement under certain specified circumstances, Vapotherm will be required to pay Perceptive a termination fee of $1.0 million. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The board of directors of Perceptive also approved the agreement. The transaction is expected to close in the second half of 2024. Eric Blanchard and Amelia Runyan Davis of Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor and fairness opinion provider to the Special Committee and Paul Kinsella and Sarah Young of Ropes & Gray LLP is acting as legal counsel to the Vapotherm. Haim Zaltzman and Daniel Mun of Latham & Watkins LLP acted as legal counsel for SLR Investment Corp., public fund managed by SLR Capital Partners, LLC. Vapotherm has retained Morrow Sodali LLC, a proxy solicitor, to solicit proxies in connection with the Special Meeting at a cost of approximately $20,000 plus expenses. Scalar received a fee of $140,000 from Vapotherm for providing its services and rendering its opinion. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on September 20, 2024. Effective as of the closing of the merger, trading of Vapotherm’s common stock has been suspended on OTCQX, and Vapotherm has requested that its common stock be delisted from OTCQX. Vapotherm shareholders approved the transaction on September 19, 2024.お知らせ • Jun 18Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The transaction is expected to close in the second half of 2024. Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor to the Special Committee and Ropes & Gray LLP is acting as legal counsel to the Vapotherm.お知らせ • Mar 15Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADEVapotherm, Inc. announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference. The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th. The device is designed to reduce hospital readmissions, improve patient quality of life, and reduce HME costs for late-stage hypercapnic COPD patients. In addition to VAPS and volume control/assist ventilation modes and Vapotherm's proven high velocity therapy, the ventilator incorporates a built-in medical grade humidifier and integrated Bluetooth pulse oximetry and spirometry. The Access365 Home Ventilation Solution also includes cloud connectivity to enable remote data retrieval and system upgrades and a patient engagement platform which breaks the cycle of symptom exacerbation and readmission through early identification of worsening symptoms allowing more rapid clinical intervention. This proprietary algorithm resulted in up to a 41% reduction in late-stage COPD hospital readmissions. Vapotherm anticipates receiving FDA clearance for Access365 in early 2025.お知らせ • Dec 15The New York Stock Exchange to Commence Delisting Proceedings against VapothermThe New York Stock Exchange (‘NYSE’, the ‘Exchange’) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Vapotherm, Inc. (the ‘Company’) from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s common stock pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.お知らせ • Nov 11Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023Vapotherm, Inc. revised revenue guidance for the full Year 2023. The Company now expects full year revenue to be between $69 million and $71 million, a decrease from the Company’s previous fiscal outlook of $70 million to $73 million.お知らせ • Nov 02Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023Vapotherm, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023お知らせ • Sep 26Vapotherm Announces Presentation of an Investigator-Initiated Clinical Trial, 'High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma - a Feasibility Randomized Controlled Trial' at the European Respiratory Society International Congress 2023Vapotherm, Inc. announced the presentation of an Investigator-initiated clinical trial, “High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled trial” at the European Respiratory Society International Congress 2023. The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs. Hector Rojas-Anaya and Paul Seddon. Children who presented to the Emergency Department with acute, severe, asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to either HVNI or standard nasal oxygen therapy. 86% (19/22) of children treated with standard oxygen required escalation of therapy, while only 61% (17/28) of children treated with HVNI needed further escalation. In addition, children treated with HVNI met hospital discharge criteria in a median time of 29 hours, compared to a median time of 37 hours for those treated with standard oxygen. Studies of acute asthma and other emergent conditions are limited, in part, by the challenge of obtaining informed consent. This study demonstrated the feasibility of pediatric emergency studies utilizing coordinated care and delayed informed consent.お知らせ • Aug 09Vapotherm, Inc. Revises Earnings Guidance for Fiscal 2023Vapotherm, Inc. revised earnings guidance For fiscal 2023. For the period, the Company now expects full year revenue to be between $70 million and $73 million, a decrease from its previous expectation of $77 million to $79 million. The Company now expects full year gross margins of 43% to 45%, a decrease from its previous expectation of 48% to 50%.お知らせ • Jul 26Vapotherm, Inc. to Report Q2, 2023 Results on Aug 08, 2023Vapotherm, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023お知らせ • May 05+ 1 more updateVapotherm, Inc. Reports Impairment of Long-Lived and Intangible Assets for the First Quarter Ended March 31, 2023Vapotherm, Inc. reported impairment of long-lived and intangible assets for the first quarter ended March 31, 2023. For the quarter, the company reported impairment of long-lived and intangible assets of $432,000.お知らせ • Feb 10Vapotherm Receives Price Cure Notification Letter from the NYSE Indicates its Stock Price Above the NYSE's Minimum RequirementVapotherm, Inc. announced that with respect to the previously reported two delisting notices from the New York Stock Exchange (NYSE) in 2022, the company reported that it recently received a price cure notification letter from the NYSE indicating the company’s stock price was above the NYSE’s minimum requirement of one dollar per share based on a 30-trading day average. Accordingly, the company is no longer considered below the one dollar continued listing criterion. The company recently received a plan acceptance letter from the NYSE indicating it had accepted the company’s previously submitted business plan to cure its non-compliance with its market capitalization requirement. As set forth in the acceptance letter, the NYSE will continue listing the Company and will perform quarterly reviews for an 18-month period that started September 27, 2022 (the date the delisting notice was received by the Company) for compliance with the goals and initiatives outlined in the Company’s business plan, which are consistent with the key initiatives the Company has publicly disclosed. The Company will need to achieve the minimum continued listing standards of either average global market capitalization over a consecutive 30 trading-day period of $50 million or total stockholders’ equity of $50 million at the completion of the 18-month period.お知らせ • Feb 09+ 2 more updatesVapotherm, Inc. to Report Q4, 2022 Results on Feb 23, 2023Vapotherm, Inc. announced that they will report Q4, 2022 results After-Market on Feb 23, 2023Seeking Alpha • Feb 08Vapotherm announces $23M private placementGlobal medical technology company, Vapotherm (NYSE:VAPO) has entered into a securities purchase agreement with investors through a private placement financing for gross proceeds of ~$23M. Pursuant to the agreement, the company agreed to issue 17.5M shares and pre-funded warrants to purchase up to 4.4M shares. The pre-funded warrants will have a term of 30 years and an exercise price of $0.001 per share. Closing expected to occur on February 10, 2023. Net proceeds from the offering primarily for sales and marketing, working capital, and other general corporate purposes. Stock trades 8% higher.Seeking Alpha • Nov 02Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02MVapotherm press release (NYSE:VAPO): Q3 GAAP EPS of -$0.98 misses by $0.20. Revenue of $13.5M (-64.6% Y/Y) misses by $3.02M. Fiscal 2022 Outlook For fiscal 2022, the Company expects net revenue to be in the range of $64 million to $66 million vs $73.94M consensus.Seeking Alpha • Aug 04Vapotherm draws downgrade at William Blair after 2Q resultsVapotherm, Inc. (NYSE:VAPO), a high-velocity therapy provider targeting patients with respiratory distress, continues to trade sharply lower after the company reported lower-than-expected 2Q 2022 results that prompted William Blair to downgrade its shares. The analysts led by Margaret Kaczor attribute the revenue miss to pressure on disposables as hospitals destocked the inventory purchased during the Omicron wave. However, the team remains optimistic about the benefit Vapotherm (VAPO) can count on due to the sizable installed base established during the COVID. In addition, they highlight the management's long-term strategy to become a patient management company for complex lung disease. However, they downgrade the stock to Market Perform from Outperform, noting the concerns over low liquidity and near-term uncertainty. Wall Street has remained bullish on Vapotherm (VAPO) stock, with an average rating of Buy from analysts, while Seeking Alpha Author ratings indicated a Hold rating. However, Seeking Alpha's quant system, which consistently beats the market, continued to rate Vapotherm (VAPO) a Strong Sell since March.Price Target Changed • Jul 06Price target decreased to US$4.83Down from US$5.50, the current price target is an average from 4 analysts. New target price is 94% above last closing price of US$2.49. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.11 next year compared to a net loss per share of US$2.31 last year.Seeking Alpha • May 11Vapotherm: Out Of AirVapotherm has seen a boom induced by the pandemic reverse violently. The pandemic has not boosted Vapotherm's business, as losses have only increased during this period of time. With revenues down to much lower levels and losses being very substantial, there are no (quick) fixes in sight.Major Estimate Revision • Mar 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$102.9m to US$104.5m. Forecast EPS reduced from -US$2.24 to -US$2.57 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target down from US$39.00 to US$27.00. Share price rose 17% to US$14.89 over the past week.Reported Earnings • Feb 27Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$2.31 loss per share (down from US$2.16 loss in FY 2020). Revenue: US$113.3m (down 9.9% from FY 2020). Net loss: US$59.8m (loss widened 16% from FY 2020). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.6%. Over the next year, revenue is expected to shrink by 9.6% compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Price Target Changed • Feb 26Price target decreased to US$34.33Down from US$41.00, the current price target is an average from 4 analysts. New target price is 125% above last closing price of US$15.29. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$2.23 next year compared to a net loss per share of US$2.16 last year.分析記事 • Jan 24Is Vapotherm (NYSE:VAPO) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.52 loss per share (vs US$0.49 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: US$38.1m (up 25% from 3Q 2020). Net loss: US$13.6m (loss widened 9.0% from 3Q 2020).Executive Departure • Oct 12Chief Accounting Officer Joel Dube has left the companyOn the 6th of October, Joel Dube's tenure as Chief Accounting Officer ended. We don't have any record of a personal shareholding under Joel's name. A total of 4 executives have left over the last 12 months. The current median tenure of the management team is 6.46 years.Recent Insider Transactions Derivative • Aug 15Senior VP notifies of intention to sell stockJohn Landry intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of August. If the sale is conducted around the recent share price of US$27.51, it would amount to US$550k. Since September 2020, John's direct individual holding has decreased from 117.39k shares to 108.71k. Company insiders have collectively bought US$4.3m more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • Aug 11Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.35 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$20.6m (down 41% from 2Q 2020). Net loss: US$17.3m (loss widened 115% from 2Q 2020).Recent Insider Transactions Derivative • Jul 31Senior VP & Chief Commercial Officer exercised options and sold US$170k worth of stockOn the 28th of July, Gregoire Ramade exercised 8k options at a strike price of around US$3.78 and sold these shares for an average price of US$25.00 per share. This trade did not impact their existing holding. Since September 2020, Gregoire has owned 10.71k shares directly. Company insiders have collectively bought US$8.4m more than they sold, via options and on-market transactions, in the last 12 months.Seeking Alpha • Jul 11Vapotherm: Hardly Breathing RoomVapotherm has benefited from the pandemic, at least sales saw a boost, but earnings did not. 2021 saw a solid start to the year, but the guidance for the remainder of the year is not inspiring, both in terms of sales and losses. Given all of this, I am not surprised to see shares under pressure, as I think it is too early to go bottom fishing here just yet.Recent Insider Transactions • Jun 30Insider recently bought US$4.8m worth of stockOn the 28th of June, Thomas Smith bought around 200k shares on-market at roughly US$23.84 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$9.6m more in shares than they have sold in the last 12 months.Executive Departure • Jun 25Independent Director Marina Hahn has left the companyOn the 22nd of June, Marina Hahn's tenure as Independent Director ended after 3.7 years in the role. As of March 2021, Marina still personally held 20.68k shares (US$497k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 6.13 years.Recent Insider Transactions • May 19Independent Chairman of the Board recently bought US$170k worth of stockOn the 13th of May, James Liken bought around 10k shares on-market at roughly US$16.99 per share. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.分析記事 • May 10Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • May 06First quarter 2021 earnings released: US$0.40 loss per share (vs US$0.66 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$32.3m (up 69% from 1Q 2020). Net loss: US$10.4m (loss narrowed 25% from 1Q 2020).分析記事 • Mar 12The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More SharesInvestors who take an interest in Vapotherm, Inc. ( NYSE:VAPO ) should definitely note that the Independent Director...Recent Insider Transactions • Mar 12Independent Director recently bought US$109k worth of stockOn the 4th of March, Anthony Arnerich bought around 5k shares on-market at roughly US$21.84 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$4.7m more in shares than they have sold in the last 12 months.分析記事 • Mar 11Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last YearVapotherm, Inc. ( NYSE:VAPO ) shareholders have seen the share price descend 29% over the month. Despite this, the...Reported Earnings • Feb 25Full year 2020 earnings released: US$2.16 loss per share (vs US$2.74 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses were not reduced. Full year 2020 results: Revenue: US$125.7m (up 161% from FY 2019). Net loss: US$51.5m (flat on FY 2019).Analyst Estimate Surprise Post Earnings • Feb 25Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 6.0%. Over the next year, revenue is expected to shrink by 29% compared to a 20% growth forecast for the Medical Equipment industry in the US.Is New 90 Day High Low • Feb 25New 90-day low: US$23.17The company is down 9.0% from its price of US$25.37 on 27 November 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period.Recent Insider Transactions Derivative • Jan 28Senior VP & Chief Commercial Officer notifies of intention to sell stockGregoire Ramade intends to sell roughly 8.00k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of January. If the sale is conducted around the recent share price of US$31.92, it would amount to US$255k. Since March 2020, Gregoire's direct individual holding has decreased from 88.25k shares to 10.71k. Company insiders have collectively bought US$1.8m more than they sold, via options and on-market transactions, in the last 12 months.Recent Insider Transactions Derivative • Jan 23Senior VP & Chief Commercial Officer exercised options and sold US$56k worth of stockOn the 20th of January, Gregoire Ramade exercised 2.00k options at a strike price of around US$3.78 and sold these shares for an average price of US$31.92 per share. This trade did not impact their existing holding. Since March 2020, Gregoire's direct individual holding has decreased from 88.25k shares to 10.71k. Company insiders have collectively bought US$1.8m more than they sold, via options and on-market transactions, in the last 12 months.分析記事 • Jan 19Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Jan 13New 90-day high: US$32.08The company is up 7.0% from its price of US$29.95 on 14 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.分析記事 • Dec 14Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On SharesPotential Vapotherm, Inc. ( NYSE:VAPO ) shareholders may wish to note that insider Thomas Smith recently bought US$217k...Recent Insider Transactions • Dec 13Insider recently bought US$217k worth of stockOn the 9th of December, Thomas Smith bought around 8k shares on-market at roughly US$27.14 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$4.6m more in shares than they have sold in the last 12 months.分析記事 • Dec 11Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...Major Estimate Revision • Dec 03Analysts update estimatesThe 2020 consensus revenue estimate increased from US$103.9m to US$117.0m. Earning per share (EPS) estimate remained mostly unchanged at -US$2.05. The Medical Equipment industry in the US is expected to see an average net income growth of 25% next year. The consensus price target of US$42.67 was unchanged from the last update. Share price is up 9.1% to US$26.38 over the past week.Is New 90 Day High Low • Nov 10New 90-day low: US$23.44The company is down 19% from its price of US$28.86 on 12 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 06Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 27%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is expected to shrink by 11% compared to a 16% growth forecast for the Medical Equipment industry in the US.Reported Earnings • Nov 06Third quarter 2020 earnings released: US$0.49 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$30.6m (up 183% from 3Q 2019). Net loss: US$12.4m (loss narrowed 2.5% from 3Q 2019).Price Target Changed • Nov 06Price target lowered to US$42.67Down from US$47.33, the current price target is an average from 4 analysts. The new target price is 51% above the current share price of US$28.26. As of last close, the stock is up 226% over the past year.株主還元VAPOUS Medical EquipmentUS 市場7D0.5%-3.5%1.3%1Y-22.2%-21.9%27.7%株主還元を見る業界別リターン: VAPO過去 1 年間で-21.9 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: VAPOは、過去 1 年間で27.7 % のリターンを上げたUS市場を下回りました。価格変動Is VAPO's price volatile compared to industry and market?VAPO volatilityVAPO Average Weekly Movement1.7%Medical Equipment Industry Average Movement8.5%Market Average Movement7.2%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.0%安定した株価: VAPOの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: VAPOの 週次ボラティリティ は、過去 1 年間で27%から2%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト1993182Joe Armywww.vapotherm.com医療技術企業であるVapotherm, Inc.は、米国内外で呼吸困難に苦しむ様々な年齢の患者を治療するために使用される独自の高速度療法製品の開発と商品化に注力している。同社は、HVT 2.0、Precision Flow Hi-VNI、Precision Flow Plus、Precision Flow Classicなどの高速度療法システムを提供しており、加熱、加湿、酸素化された空気を高速度で患者に供給することで、患者に非侵襲的な換気サポートを提供している。また、Vapotherm Transfer Unitなどの関連製品も提供している。Vapotherm Transfer Unitは、患者が病院内のケアエリア間を移動したり、治療中に歩行したりできるようにするもので、Q50コンプレッサーは、壁のガス源にアクセスできない病院内のエリアで、プレシジョン・フロー・システムを作動させるのに必要な圧縮空気を供給する；エアロゾル化溶液の送達を容易にするエアロゾルエアロネブアダプター、患者へのエアロゾル溶液の連続的および断続的な送達を合理化するように設計されたエアロゾル使い捨て患者回路、および患者を機械的人工呼吸から離脱させるために使用される気管切開カラーへのHigh Velocity Therapyシステムの接続を簡素化する気管切開アダプター。さらに、皮膚に優しく接触するプロソフトカニューレ、使い捨てディスポーザブルと鼻腔インターフェースからなるディスポーザブル製品、臨床医が酸素濃度を目標範囲内に維持するのを助ける酸素アシストモジュールも提供している。バポサーム社は1993年に設立され、ニューハンプシャー州エクセターに本社を置いている。もっと見るVapotherm, Inc. 基礎のまとめVapotherm の収益と売上を時価総額と比較するとどうか。VAPO 基礎統計学時価総額US$13.61m収益（TTM）-US$54.42m売上高(TTM)US$70.92m0.2xP/Sレシオ-0.2xPER（株価収益率VAPO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計VAPO 損益計算書（TTM）収益US$70.92m売上原価US$37.71m売上総利益US$33.21mその他の費用US$87.63m収益-US$54.42m直近の収益報告Jun 30, 2024次回決算日該当なし一株当たり利益（EPS）-8.71グロス・マージン46.82%純利益率-76.74%有利子負債／自己資本比率-145.6%VAPO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/09/19 20:38終値2024/09/19 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vapotherm, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Robert HopkinsBofA Global ResearchMichael GormanBTIGWilliam PlovanicCanaccord Genuity2 その他のアナリストを表示
お知らせ • Sep 20Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC executed the non binding term sheet to acquire Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on April 29, 2024. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. from a group of shareholders for $15.2 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Upon termination of the Merger Agreement under certain specified circumstances, Vapotherm will be required to pay Perceptive a termination fee of $1.0 million. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The board of directors of Perceptive also approved the agreement. The transaction is expected to close in the second half of 2024. Eric Blanchard and Amelia Runyan Davis of Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor and fairness opinion provider to the Special Committee and Paul Kinsella and Sarah Young of Ropes & Gray LLP is acting as legal counsel to the Vapotherm. Haim Zaltzman and Daniel Mun of Latham & Watkins LLP acted as legal counsel for SLR Investment Corp., public fund managed by SLR Capital Partners, LLC. Vapotherm has retained Morrow Sodali LLC, a proxy solicitor, to solicit proxies in connection with the Special Meeting at a cost of approximately $20,000 plus expenses. Scalar received a fee of $140,000 from Vapotherm for providing its services and rendering its opinion. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on September 20, 2024. Effective as of the closing of the merger, trading of Vapotherm’s common stock has been suspended on OTCQX, and Vapotherm has requested that its common stock be delisted from OTCQX. Vapotherm shareholders approved the transaction on September 19, 2024.
お知らせ • Jun 18Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The transaction is expected to close in the second half of 2024. Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor to the Special Committee and Ropes & Gray LLP is acting as legal counsel to the Vapotherm.
お知らせ • Mar 15Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADEVapotherm, Inc. announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference. The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th. The device is designed to reduce hospital readmissions, improve patient quality of life, and reduce HME costs for late-stage hypercapnic COPD patients. In addition to VAPS and volume control/assist ventilation modes and Vapotherm's proven high velocity therapy, the ventilator incorporates a built-in medical grade humidifier and integrated Bluetooth pulse oximetry and spirometry. The Access365 Home Ventilation Solution also includes cloud connectivity to enable remote data retrieval and system upgrades and a patient engagement platform which breaks the cycle of symptom exacerbation and readmission through early identification of worsening symptoms allowing more rapid clinical intervention. This proprietary algorithm resulted in up to a 41% reduction in late-stage COPD hospital readmissions. Vapotherm anticipates receiving FDA clearance for Access365 in early 2025.
お知らせ • Dec 15The New York Stock Exchange to Commence Delisting Proceedings against VapothermThe New York Stock Exchange (‘NYSE’, the ‘Exchange’) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Vapotherm, Inc. (the ‘Company’) from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s common stock pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
お知らせ • Nov 11Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023Vapotherm, Inc. revised revenue guidance for the full Year 2023. The Company now expects full year revenue to be between $69 million and $71 million, a decrease from the Company’s previous fiscal outlook of $70 million to $73 million.
お知らせ • Nov 02Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023Vapotherm, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
お知らせ • Sep 20Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC executed the non binding term sheet to acquire Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on April 29, 2024. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. from a group of shareholders for $15.2 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Upon termination of the Merger Agreement under certain specified circumstances, Vapotherm will be required to pay Perceptive a termination fee of $1.0 million. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The board of directors of Perceptive also approved the agreement. The transaction is expected to close in the second half of 2024. Eric Blanchard and Amelia Runyan Davis of Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor and fairness opinion provider to the Special Committee and Paul Kinsella and Sarah Young of Ropes & Gray LLP is acting as legal counsel to the Vapotherm. Haim Zaltzman and Daniel Mun of Latham & Watkins LLP acted as legal counsel for SLR Investment Corp., public fund managed by SLR Capital Partners, LLC. Vapotherm has retained Morrow Sodali LLC, a proxy solicitor, to solicit proxies in connection with the Special Meeting at a cost of approximately $20,000 plus expenses. Scalar received a fee of $140,000 from Vapotherm for providing its services and rendering its opinion. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on September 20, 2024. Effective as of the closing of the merger, trading of Vapotherm’s common stock has been suspended on OTCQX, and Vapotherm has requested that its common stock be delisted from OTCQX. Vapotherm shareholders approved the transaction on September 19, 2024.
お知らせ • Jun 18Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The transaction is expected to close in the second half of 2024. Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor to the Special Committee and Ropes & Gray LLP is acting as legal counsel to the Vapotherm.
お知らせ • Mar 15Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADEVapotherm, Inc. announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference. The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th. The device is designed to reduce hospital readmissions, improve patient quality of life, and reduce HME costs for late-stage hypercapnic COPD patients. In addition to VAPS and volume control/assist ventilation modes and Vapotherm's proven high velocity therapy, the ventilator incorporates a built-in medical grade humidifier and integrated Bluetooth pulse oximetry and spirometry. The Access365 Home Ventilation Solution also includes cloud connectivity to enable remote data retrieval and system upgrades and a patient engagement platform which breaks the cycle of symptom exacerbation and readmission through early identification of worsening symptoms allowing more rapid clinical intervention. This proprietary algorithm resulted in up to a 41% reduction in late-stage COPD hospital readmissions. Vapotherm anticipates receiving FDA clearance for Access365 in early 2025.
お知らせ • Dec 15The New York Stock Exchange to Commence Delisting Proceedings against VapothermThe New York Stock Exchange (‘NYSE’, the ‘Exchange’) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Vapotherm, Inc. (the ‘Company’) from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s common stock pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
お知らせ • Nov 11Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023Vapotherm, Inc. revised revenue guidance for the full Year 2023. The Company now expects full year revenue to be between $69 million and $71 million, a decrease from the Company’s previous fiscal outlook of $70 million to $73 million.
お知らせ • Nov 02Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023Vapotherm, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
お知らせ • Sep 26Vapotherm Announces Presentation of an Investigator-Initiated Clinical Trial, 'High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma - a Feasibility Randomized Controlled Trial' at the European Respiratory Society International Congress 2023Vapotherm, Inc. announced the presentation of an Investigator-initiated clinical trial, “High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled trial” at the European Respiratory Society International Congress 2023. The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs. Hector Rojas-Anaya and Paul Seddon. Children who presented to the Emergency Department with acute, severe, asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to either HVNI or standard nasal oxygen therapy. 86% (19/22) of children treated with standard oxygen required escalation of therapy, while only 61% (17/28) of children treated with HVNI needed further escalation. In addition, children treated with HVNI met hospital discharge criteria in a median time of 29 hours, compared to a median time of 37 hours for those treated with standard oxygen. Studies of acute asthma and other emergent conditions are limited, in part, by the challenge of obtaining informed consent. This study demonstrated the feasibility of pediatric emergency studies utilizing coordinated care and delayed informed consent.
お知らせ • Aug 09Vapotherm, Inc. Revises Earnings Guidance for Fiscal 2023Vapotherm, Inc. revised earnings guidance For fiscal 2023. For the period, the Company now expects full year revenue to be between $70 million and $73 million, a decrease from its previous expectation of $77 million to $79 million. The Company now expects full year gross margins of 43% to 45%, a decrease from its previous expectation of 48% to 50%.
お知らせ • Jul 26Vapotherm, Inc. to Report Q2, 2023 Results on Aug 08, 2023Vapotherm, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023
お知らせ • May 05+ 1 more updateVapotherm, Inc. Reports Impairment of Long-Lived and Intangible Assets for the First Quarter Ended March 31, 2023Vapotherm, Inc. reported impairment of long-lived and intangible assets for the first quarter ended March 31, 2023. For the quarter, the company reported impairment of long-lived and intangible assets of $432,000.
お知らせ • Feb 10Vapotherm Receives Price Cure Notification Letter from the NYSE Indicates its Stock Price Above the NYSE's Minimum RequirementVapotherm, Inc. announced that with respect to the previously reported two delisting notices from the New York Stock Exchange (NYSE) in 2022, the company reported that it recently received a price cure notification letter from the NYSE indicating the company’s stock price was above the NYSE’s minimum requirement of one dollar per share based on a 30-trading day average. Accordingly, the company is no longer considered below the one dollar continued listing criterion. The company recently received a plan acceptance letter from the NYSE indicating it had accepted the company’s previously submitted business plan to cure its non-compliance with its market capitalization requirement. As set forth in the acceptance letter, the NYSE will continue listing the Company and will perform quarterly reviews for an 18-month period that started September 27, 2022 (the date the delisting notice was received by the Company) for compliance with the goals and initiatives outlined in the Company’s business plan, which are consistent with the key initiatives the Company has publicly disclosed. The Company will need to achieve the minimum continued listing standards of either average global market capitalization over a consecutive 30 trading-day period of $50 million or total stockholders’ equity of $50 million at the completion of the 18-month period.
お知らせ • Feb 09+ 2 more updatesVapotherm, Inc. to Report Q4, 2022 Results on Feb 23, 2023Vapotherm, Inc. announced that they will report Q4, 2022 results After-Market on Feb 23, 2023
Seeking Alpha • Feb 08Vapotherm announces $23M private placementGlobal medical technology company, Vapotherm (NYSE:VAPO) has entered into a securities purchase agreement with investors through a private placement financing for gross proceeds of ~$23M. Pursuant to the agreement, the company agreed to issue 17.5M shares and pre-funded warrants to purchase up to 4.4M shares. The pre-funded warrants will have a term of 30 years and an exercise price of $0.001 per share. Closing expected to occur on February 10, 2023. Net proceeds from the offering primarily for sales and marketing, working capital, and other general corporate purposes. Stock trades 8% higher.
Seeking Alpha • Nov 02Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02MVapotherm press release (NYSE:VAPO): Q3 GAAP EPS of -$0.98 misses by $0.20. Revenue of $13.5M (-64.6% Y/Y) misses by $3.02M. Fiscal 2022 Outlook For fiscal 2022, the Company expects net revenue to be in the range of $64 million to $66 million vs $73.94M consensus.
Seeking Alpha • Aug 04Vapotherm draws downgrade at William Blair after 2Q resultsVapotherm, Inc. (NYSE:VAPO), a high-velocity therapy provider targeting patients with respiratory distress, continues to trade sharply lower after the company reported lower-than-expected 2Q 2022 results that prompted William Blair to downgrade its shares. The analysts led by Margaret Kaczor attribute the revenue miss to pressure on disposables as hospitals destocked the inventory purchased during the Omicron wave. However, the team remains optimistic about the benefit Vapotherm (VAPO) can count on due to the sizable installed base established during the COVID. In addition, they highlight the management's long-term strategy to become a patient management company for complex lung disease. However, they downgrade the stock to Market Perform from Outperform, noting the concerns over low liquidity and near-term uncertainty. Wall Street has remained bullish on Vapotherm (VAPO) stock, with an average rating of Buy from analysts, while Seeking Alpha Author ratings indicated a Hold rating. However, Seeking Alpha's quant system, which consistently beats the market, continued to rate Vapotherm (VAPO) a Strong Sell since March.
Price Target Changed • Jul 06Price target decreased to US$4.83Down from US$5.50, the current price target is an average from 4 analysts. New target price is 94% above last closing price of US$2.49. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.11 next year compared to a net loss per share of US$2.31 last year.
Seeking Alpha • May 11Vapotherm: Out Of AirVapotherm has seen a boom induced by the pandemic reverse violently. The pandemic has not boosted Vapotherm's business, as losses have only increased during this period of time. With revenues down to much lower levels and losses being very substantial, there are no (quick) fixes in sight.
Major Estimate Revision • Mar 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$102.9m to US$104.5m. Forecast EPS reduced from -US$2.24 to -US$2.57 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target down from US$39.00 to US$27.00. Share price rose 17% to US$14.89 over the past week.
Reported Earnings • Feb 27Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$2.31 loss per share (down from US$2.16 loss in FY 2020). Revenue: US$113.3m (down 9.9% from FY 2020). Net loss: US$59.8m (loss widened 16% from FY 2020). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.6%. Over the next year, revenue is expected to shrink by 9.6% compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Price Target Changed • Feb 26Price target decreased to US$34.33Down from US$41.00, the current price target is an average from 4 analysts. New target price is 125% above last closing price of US$15.29. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$2.23 next year compared to a net loss per share of US$2.16 last year.
分析記事 • Jan 24Is Vapotherm (NYSE:VAPO) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.52 loss per share (vs US$0.49 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: US$38.1m (up 25% from 3Q 2020). Net loss: US$13.6m (loss widened 9.0% from 3Q 2020).
Executive Departure • Oct 12Chief Accounting Officer Joel Dube has left the companyOn the 6th of October, Joel Dube's tenure as Chief Accounting Officer ended. We don't have any record of a personal shareholding under Joel's name. A total of 4 executives have left over the last 12 months. The current median tenure of the management team is 6.46 years.
Recent Insider Transactions Derivative • Aug 15Senior VP notifies of intention to sell stockJohn Landry intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of August. If the sale is conducted around the recent share price of US$27.51, it would amount to US$550k. Since September 2020, John's direct individual holding has decreased from 117.39k shares to 108.71k. Company insiders have collectively bought US$4.3m more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • Aug 11Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.35 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$20.6m (down 41% from 2Q 2020). Net loss: US$17.3m (loss widened 115% from 2Q 2020).
Recent Insider Transactions Derivative • Jul 31Senior VP & Chief Commercial Officer exercised options and sold US$170k worth of stockOn the 28th of July, Gregoire Ramade exercised 8k options at a strike price of around US$3.78 and sold these shares for an average price of US$25.00 per share. This trade did not impact their existing holding. Since September 2020, Gregoire has owned 10.71k shares directly. Company insiders have collectively bought US$8.4m more than they sold, via options and on-market transactions, in the last 12 months.
Seeking Alpha • Jul 11Vapotherm: Hardly Breathing RoomVapotherm has benefited from the pandemic, at least sales saw a boost, but earnings did not. 2021 saw a solid start to the year, but the guidance for the remainder of the year is not inspiring, both in terms of sales and losses. Given all of this, I am not surprised to see shares under pressure, as I think it is too early to go bottom fishing here just yet.
Recent Insider Transactions • Jun 30Insider recently bought US$4.8m worth of stockOn the 28th of June, Thomas Smith bought around 200k shares on-market at roughly US$23.84 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$9.6m more in shares than they have sold in the last 12 months.
Executive Departure • Jun 25Independent Director Marina Hahn has left the companyOn the 22nd of June, Marina Hahn's tenure as Independent Director ended after 3.7 years in the role. As of March 2021, Marina still personally held 20.68k shares (US$497k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 6.13 years.
Recent Insider Transactions • May 19Independent Chairman of the Board recently bought US$170k worth of stockOn the 13th of May, James Liken bought around 10k shares on-market at roughly US$16.99 per share. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.
分析記事 • May 10Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • May 06First quarter 2021 earnings released: US$0.40 loss per share (vs US$0.66 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$32.3m (up 69% from 1Q 2020). Net loss: US$10.4m (loss narrowed 25% from 1Q 2020).
分析記事 • Mar 12The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More SharesInvestors who take an interest in Vapotherm, Inc. ( NYSE:VAPO ) should definitely note that the Independent Director...
Recent Insider Transactions • Mar 12Independent Director recently bought US$109k worth of stockOn the 4th of March, Anthony Arnerich bought around 5k shares on-market at roughly US$21.84 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$4.7m more in shares than they have sold in the last 12 months.
分析記事 • Mar 11Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last YearVapotherm, Inc. ( NYSE:VAPO ) shareholders have seen the share price descend 29% over the month. Despite this, the...
Reported Earnings • Feb 25Full year 2020 earnings released: US$2.16 loss per share (vs US$2.74 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses were not reduced. Full year 2020 results: Revenue: US$125.7m (up 161% from FY 2019). Net loss: US$51.5m (flat on FY 2019).
Analyst Estimate Surprise Post Earnings • Feb 25Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 6.0%. Over the next year, revenue is expected to shrink by 29% compared to a 20% growth forecast for the Medical Equipment industry in the US.
Is New 90 Day High Low • Feb 25New 90-day low: US$23.17The company is down 9.0% from its price of US$25.37 on 27 November 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period.
Recent Insider Transactions Derivative • Jan 28Senior VP & Chief Commercial Officer notifies of intention to sell stockGregoire Ramade intends to sell roughly 8.00k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of January. If the sale is conducted around the recent share price of US$31.92, it would amount to US$255k. Since March 2020, Gregoire's direct individual holding has decreased from 88.25k shares to 10.71k. Company insiders have collectively bought US$1.8m more than they sold, via options and on-market transactions, in the last 12 months.
Recent Insider Transactions Derivative • Jan 23Senior VP & Chief Commercial Officer exercised options and sold US$56k worth of stockOn the 20th of January, Gregoire Ramade exercised 2.00k options at a strike price of around US$3.78 and sold these shares for an average price of US$31.92 per share. This trade did not impact their existing holding. Since March 2020, Gregoire's direct individual holding has decreased from 88.25k shares to 10.71k. Company insiders have collectively bought US$1.8m more than they sold, via options and on-market transactions, in the last 12 months.
分析記事 • Jan 19Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Jan 13New 90-day high: US$32.08The company is up 7.0% from its price of US$29.95 on 14 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.
分析記事 • Dec 14Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On SharesPotential Vapotherm, Inc. ( NYSE:VAPO ) shareholders may wish to note that insider Thomas Smith recently bought US$217k...
Recent Insider Transactions • Dec 13Insider recently bought US$217k worth of stockOn the 9th of December, Thomas Smith bought around 8k shares on-market at roughly US$27.14 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$4.6m more in shares than they have sold in the last 12 months.
分析記事 • Dec 11Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...
Major Estimate Revision • Dec 03Analysts update estimatesThe 2020 consensus revenue estimate increased from US$103.9m to US$117.0m. Earning per share (EPS) estimate remained mostly unchanged at -US$2.05. The Medical Equipment industry in the US is expected to see an average net income growth of 25% next year. The consensus price target of US$42.67 was unchanged from the last update. Share price is up 9.1% to US$26.38 over the past week.
Is New 90 Day High Low • Nov 10New 90-day low: US$23.44The company is down 19% from its price of US$28.86 on 12 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 06Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 27%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is expected to shrink by 11% compared to a 16% growth forecast for the Medical Equipment industry in the US.
Reported Earnings • Nov 06Third quarter 2020 earnings released: US$0.49 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$30.6m (up 183% from 3Q 2019). Net loss: US$12.4m (loss narrowed 2.5% from 3Q 2019).
Price Target Changed • Nov 06Price target lowered to US$42.67Down from US$47.33, the current price target is an average from 4 analysts. The new target price is 51% above the current share price of US$28.26. As of last close, the stock is up 226% over the past year.
